Testing a new imaging agent for rectal cancer lymph nodes
Part of Cancer, Digestive system clinical trials.
This trial tests a new nanoparticle-based imaging agent to better see lymph nodes near the rectum. It first checks healthy volunteers for safety, then studies people with rectal cancer to see if it can help guide surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For people with rectal cancer: you must have a confirmed diagnosis and be scheduled for surgery.
- You must be able to have a small probe placed in the rectum (the tumor should not block it).
- You must not have a pacemaker or metal implants in your body.
- You cannot have had radiation therapy to the rectum in the past.
- You must be willing to use birth control (if male) or be unable to become pregnant (if female).
- You must not have any other active cancer or serious health conditions that could affect the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced MRI scans to see how well rectal cancer is responding to radiotherapy. It may help doctors better understand which treatments work best for patients with more advanced disease.
This trial tests a magnetic tracer to find lymph nodes near the stomach during surgery. It aims to help doctors know if the cancer has spread, which can guide treatment decisions.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This Phase 2 study tests two different ways of giving radiation before surgery for locally advanced rectal cancer, with or without an added study drug called BMX-001. It aims to see whether the shorter/longer radiation plans and BMX-001 improve cancer control and are safe.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.